Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring?

Journal of Hepatology

Volumn 59, Issue 3, 2013, Pages 633-634

  D'Avolio, Antonio ^a   Cusato, Jessica ^a   Calcagno, Andrea ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

DRUG BLOOD LEVEL; DRUG MONITORING; GENE THERAPY; GENOTYPE; HEPATITIS C; HUMAN; LETTER; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; PYROPHOSPHATASES; RIBAVIRIN;

EID: 84882921624     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.04.038     Document Type: Letter

References (10)

1. M. Rau, F. Stickel, S. Russmann, C. Manser, P. Becker, and M. Weisskopf Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection J Hepatol 58 2013 669 675
2. A. D'Avolio, A. Ciancio, M. Siccardi, L. Baietto, M. Simiele, and S. Patanella SLC28A2 65C >T predict sustained virological response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4 J Hepatol 52 2010 S463
3. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, M. Simiele, and J. Cusato Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment Ther Drug Monit 34 2012 722 728
4. E. Snoeck, J.R. Wade, F. Duff, M. Lamb, and K. Jorga Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin Br J Clin Pharmacol 62 2006 699 709
5. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, L. Baietto, and M. Simiele Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment Ther Drug Monit 34 2012 165 170
6. A. D'Avolio, A. Ciancio, M. Siccardi, L. Baietto, M. Simiele, and G. Cariti Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4 Hepatology 54 2011 2279
7. D. Aguilar Marucco, D. Gonzalez de Requena, S. Bonora, C. Tettoni, M. Bonasso, and T. De Blasi The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon J Antimicrob Chemother 61 2008 919 924
8. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, and T. Goeser Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
9. G. Caviglia, A. D'Avolio, A. Ciancio, A. De Nicolò, L. Boglione, and M. Abate F-33 early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy Dig Liver Dis 44 2012 S42
10. S. Slavenburg, H.W. Huntjens-Fleuren, T.S. Dofferhoff, C. Richter, P.P. Koopmans, and C.P. Verwey-Van Wissen Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations Ther Drug Monit 33 2011 40 44